Taxol Articles
Amgen's Promising MGDF For Thrombocytopenia
17 February 1997
Israel: Updating The Drug Basket, Funding Innovation
10 February 1997
Dutch Call To Add PMS, PE To EU Drug Approvals
3 February 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
NIH Extends Taxol Collaboration
9 December 1996
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
SmithKline Beecham's Hycamtin Receives EU Approval
25 November 1996
Hauser Signs 3 Year Contract With Unnamed
18 November 1996
Taxol Cleared For First-Line Use In Ovarian Cancer
28 October 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
US NAPM Slams "Pediatric Research" Patent Extensions Plans
14 October 1996
Investment, Profitability And Biotechnology
14 October 1996
Clarification
19 August 1996
PhRMA Views Env Assessment Plans
5 August 1996
R-PR Launches Taxotere In USA
17 June 1996
Xenova Starts Trials Of Second Cancer Drug
17 June 1996
First Approval Of SB's Hycamtin
3 June 1996
Taxotere Cleared For Marketing In USA
20 May 1996
Volume Growth Boosts B-MS' First Quarter
6 May 1996
SB's Hycamtin Backed By US Committee
29 April 1996
B-MS Representative Office In Estonia
22 April 1996
ImClone's C225 Plus Taxol
11 March 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
Crystal Ball Gazing In Cancer Therapy
12 February 1996
Docetaxel Shows Efficacy In Ovarian Cancer
5 February 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
Taxol Improves Survival In Ovarian Cancer Patients
15 January 1996
No Drug Approval Lag, "At Least Not In The USA"
18 December 1995
Taxotere Gets EU-Wide Approval For Breast Cancer
4 December 1995
Topotecan As 1st-Line Ovarian Cancer Drug
13 November 1995
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
Cancer compounds effective against tropical parasite
30 October 1995
Patent Row Breaks Out Over Taxoid Drugs
30 October 1995
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Taxotere Clears Major Marketing Hurdle In USA
23 October 1995
Bristol-Myers research operations
31 July 1995
Strong International Sales For US Cos In 2nd Qtr
31 July 1995
Taxol Dispute In Canada
17 July 1995
Solid 2nd Qtr Earnings Growth For US Drugmakers
17 July 1995
...And US Bioscience's Ethyol
19 June 1995
Disease ManagementThe Way Forward
15 May 1995
B-M Squibb's Taxol
8 May 1995
Faulding Hopes For FDA Approval
24 April 1995
Retinoic Acid Efficacy Boost For Chemotherapy
27 February 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Taxol Receives CPMP Recommendation
30 January 1995
Polarization Concerns For Chemical/Drug Majors?
16 January 1995
Taxol Costs
2 January 1995
Neoral To Replace Ciclosporin
19 December 1994
Vertex Begins VX-710 Clinical Trials
12 December 1994
Docetaxel Approved In First Market
12 December 1994
New Anticancer Agents: Phase II Trial Results
12 December 1994
Ensuiko Sugar Aim For Water-Soluble Taxol
7 November 1994
Israeli Agreement On Health Care Costs
7 November 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Drug Registration In Malaysia
24 October 1994
Semi-Synthetic Taxol Backed In EU
17 October 1994
Ingenex Gene Therapy Started
26 September 1994
IND For CTI's Novel Cancer Drug In 1995?
26 September 1994
Titan Pharma Has Novel Approach To Biotech
26 September 1994
Lisofylline In Ph III By 2nd Qtr 1995, Says CTI
19 September 1994
BTG Cancer Drug Deal With Chinese Firm
1 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
TAXOL SHOULD ONLY USED IN TRIALS, SAYS D&TB
27 June 1994
CONFERENCE REPORT: ASCO MEETING
30 May 1994
TAXOTERE REVEALS BROAD ACTIVITY
23 May 1994
AMERICAN CYANAMID AGREEMENT
23 May 1994
MYOTROPHIN TESTED FOR POST-POLIO SYNDROME
16 May 1994
R-PR REGROUPS BIOTECH ACTIVITY
9 May 1994
ORAL CONTRACEPTIVE RECOMMENDATIONS
2 May 1994
CURRENCIES STILL A FACTOR IN US 1st QTR
2 May 1994
TAXOL APPROVED FOR BREAST CANCER
25 April 1994
MATRIX REVEALS ADV DATA AT AACR
18 April 1994
NEW TRIAL DATA ON R-PR'S TAXOTERE
21 March 1994
TOTAL SYNTHESIS OF TAXOL ACHIEVED
28 February 1994
OUTLOOK UNCERTAIN AT RHONE-POULENC IN 1994
28 February 1994
TAXOL SUPPLIES AVAILABLE
21 February 1994
TAXOL LAUNCHED AT HIGH PRICE IN FRANCE
21 February 1994
COST-CONTAINMENT, A BITTER PILL FOR INDUSTRY
21 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
VIRATEK TO FILE NDA FOR VIRAZOLE
31 January 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
B-MS LAUNCHES TAXOL IN UK
17 January 1994
GERMAN BGA CUTS DRUG WAITING LIST
17 January 1994
TAXOL APPROVABLE FOR BREAST CANCER
10 January 1994
TAXOL FOR BREAST CANCER
29 November 1993
TAXOL/FAULDING CORRECTION
22 November 1993
NCI QUESTIONS FDA TAXOL RECOMMENDATIONS
1 November 1993
US 3rd QTR AFFECTED BY STRONG DOLLAR
1 November 1993
TAXOL REVEALS FURTHER POTENTIAL
25 October 1993
EC'S CPMP BACKS TAXOL APPROVAL
27 September 1993
VESTAR/TOWERS PACLITAXEL VENTURE
20 September 1993
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
